![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Roche Wins Approval for Post-Op Breast Cancer Treatment
Roche Wins Approval for Post-Op Breast Cancer Treatment
![roche.gif](https://www.fdanews.com/ext/resources/test/Device_Images/roche.gif?t=1600727553&width=430)
May 15, 2019
The FDA approved Roche’s Kadcyla to help treat breast cancer patients after their surgeries.
Kadcyla (trastuzumab emtansine) is indicated for patients with HER2-positive early breast cancer who have residual disease after pre-surgical treatments.
The approval comes just 12 weeks after Roche submitted for it under the FDA’s Real-Time Oncology Review and Assessment Aid pilot, designed to help speed drugs through to the market.
The approval comes after Roche presented results from a Phase III trial, which reduced the risk of breast cancer coming back by half in patients in the Kadcyla group.
Upcoming Events
-
21Oct